USS Investment Management Ltd Sells 4,558 Shares of DexCom, Inc. (NASDAQ:DXCM)

USS Investment Management Ltd decreased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 5.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 86,132 shares of the medical device company's stock after selling 4,558 shares during the period. USS Investment Management Ltd's holdings in DexCom were worth $6,698,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Private Trust Co. NA grew its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. acquired a new stake in shares of DexCom during the 4th quarter valued at $33,000. TD Private Client Wealth LLC grew its holdings in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter worth $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DXCM. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Barclays lifted their price target on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a report on Monday, May 5th. Mizuho began coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Morgan Stanley raised their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Finally, Cfra Research upgraded shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.00.

DexCom Stock Performance

NASDAQ:DXCM traded up $0.68 during midday trading on Tuesday, reaching $85.19. The stock had a trading volume of 622,992 shares, compared to its average volume of 4,357,223. The stock has a market capitalization of $33.40 billion, a P/E ratio of 59.63, a PEG ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $128.63. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm's fifty day simple moving average is $73.76 and its 200-day simple moving average is $78.36.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm's revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 in the last 90 days. 0.32% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.